NASDAQ
3.28USD
+0.23 (+7.54%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9.3M
P/E
—
EPS
—
Beta
-1.04
52W range
2.07-12.5
Day range
3.06–3.30
Open
3.15
Prev close
3.05
Volume
62.5K
Avg volume
90.7K
Dividend
0.00
IPO
2021-03-18
https://www.globenewswire.com/news-release/2026/07/14/3326859/0/en/SeaStar-Medical-Supports-Advances-in-Critical-Care-of-Pediatric-Patients-with-Acute-Kidney-Injury-AKI.html · 7/14/2026+0.80
https://www.globenewswire.com/news-release/2026/06/22/3315299/0/en/SeaStar-Medical-to-Present-at-Upcoming-Investor-Summit-Conference.html · 6/22/2026+0.60
https://seekingalpha.com/article/4898245-madison-small-cap-fund-q1-2026-portfolio-activity · 5/5/2026+0.80
https://seekingalpha.com/article/4889917-icu-medical-moving-toward-cleaner-margin-leverage-and-capital-return-story · 4/10/2026+0.90
https://www.globenewswire.com/news-release/2026/03/09/3251834/0/en/SeaStar-Medical-to-Present-at-the-Life-Sciences-Investor-Forum-on-March-11th.html · 3/9/2026
https://www.globenewswire.com/news-release/2025/09/23/3154668/0/en/SeaStar-Medical-to-Present-Early-SAVE-Registry-Data-of-QUELIMMUNE-in-Pediatric-Acute-Kidney-Injury-at-the-5th-International-Symposium-on-Acute-Kidney-Injury-in-Children.html · 9/23/2025+0.80
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
